Improving the regulatory review of drugs and devices – stakeholder meetings and engagement activities

In keeping with our commitment to openness and transparency, a notice was posted to inform stakeholders on how Health Canada will handle meeting and correspondence information for specific initiatives, including Improving the regulatory review of drugs and devices. The table below lists meetings between Health Canada officials and stakeholders from August 1, 2018 until the end of the initiative in 2021. The documents listed in the table are available to members of the public upon request, for the sole purpose of ensuring greater transparency. If a Health Canada document is listed in English only and you would like it in French, please indicate this in your request. The disclosures made as part of this new policy are not part of the consultation process. Health Canada is therefore not seeking any feedback on any of these documents. To request a copy of specific documents, send your request by email, citing the meeting number.

Please note that some of the documents, hyperlinks or information in the table were provided or submitted to us as a courtesy by an individual or organization not subject to the Official Languages Act and, as such, are presented here in the official language in which they were submitted.

Oral or written communications for the purpose of making simple enquiries or requests for information that do not have any relevance, in Health Canada's view, to the development of policies, regulations or guidance related to improving the regulatory review of drugs and devices will not be published. Learn more about how Health Canada makes information, data, publications and reports available to Canadians.

Stakeholder meetings and engagement activities concerning regulatory review of drugs and activities

Meeting number for document requests	Date	Topic	Organization(s)	Type of Interaction	Purpose	Health Canada Office(s)	Document(s) shared
1	2018-10-26	Bilateral meeting with Innovative Medicines Canada (IMC) on Expansion of Priority Review Pathways: A Draft Proposal	Health Canada and IMC	Health Canada- initiated meeting	To update on Health Canada's Draft Proposal and solicit IMC's feedback on key aspects of the proposal.	Regulatory Review of Drugs and Devices Office	1. Presentation (English)
2	2018-10-26	Bilateral meeting with the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Provincial Advisory Group (PAG) for the pan-Canadian Oncology Drug Review (pCODR)	Health Canada, CADTH and PAG	Health Canada- initiated meeting	To update on Health Canada's Draft Proposal and solicit CADTH and PAG's feedback on key aspects of the proposal.	Regulatory Review of Drugs and Devices Office	1. Presentation (English)
3	2019-02-14	Workshop with the Canadian Association for Professionals in Regulatory Affairs (CAPRA) on Expansion of Priority Review Process to include consideration of healthcare system needs	Health Canada and CAPRA	CAPRA-initiated workshop	To update on Health Canada's Draft Proposal and solicit CAPRA's feedback on key aspects of the proposal.	Regulatory Review of Drugs and Devices Office	1. Presentation (English)
4	2019-06-07	Performance metrics for the Regulatory Review of Drugs and Devices initiative	Health Canada and Innovative Medicines Canada (IMC)	IMC-initiated meeting	To discuss data on drug submission timing and status that could be used to describe impact of the Regulatory Review of Drugs and Devices initiative.	Regulatory Review of Drugs and Devices Office	No data
5	2020-12-04 and 2020-12-09	Improving Access to Generics Regulatory Package: Path Forward	Health Canada and Canadian Generic Pharmaceutical Association (CGPA)	Health Canada-initiated meeting	To discuss modifications to the regulatory package and solicit CGPA’s feedback on available options	Therapeutic Products Directorate	No data